MARKET

XBIT

XBIT

Xbiotech
NASDAQ
2.330
0.000
0.00%
After Hours: 2.330 0 0.00% 16:10 06/26 EDT
OPEN
2.320
PREV CLOSE
2.330
HIGH
2.330
LOW
2.310
VOLUME
74.20K
TURNOVER
--
52 WEEK HIGH
3.610
52 WEEK LOW
2.090
MARKET CAP
71.04M
P/E (TTM)
-1.7686
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XBIT last week (0615-0619)?
Weekly Report · 5d ago
XBiotech Granted FDA Clearance For Phase 2 Study For Vilamakitug In Axial Spondyloarthritis
NASDAQ · 06/16 13:27
XBiotech to enroll patients in vilamakitug trial following FDA review
TipRanks · 06/15 13:21
XBiotech Says IND Application For V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path For U.S. Patient Enrollment
Benzinga · 06/15 13:07
XBIOTECH - IND APPLICATION FOR V-SPINE CLEARS FDA 30-DAY REVIEW WITHOUT CLINICAL HOLD
Reuters · 06/15 13:04
XBiotech vilamakitug Phase II axial spondyloarthritis IND clears FDA review without hold
PUBT · 06/15 13:00
XBIOTECH - IND APPLICATION FOR V-SPINE COMPLETES FDA REVIEW WITH NO CLINICAL HOLD
Reuters · 06/15 13:00
XBIOTECH LAUNCHES PHASE II CLINICAL TRIAL EVALUATING VILAMAKITUG FOR THE TREATMENT OF ACTIVE AXIAL SPONDYLOARTHRITIS
Reuters · 06/15 13:00
More
About XBIT
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Webull offers XBiotech Inc stock information, including NASDAQ: XBIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XBIT stock methods without spending real money on the virtual paper trading platform.